TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05068830
Drug: ExPlas
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.
Study: NCT05261490
Drug: Pegylated Liposomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
Study: NCT06327256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching BI 3000202
Study: NCT05234580
Drug: PA9159 nasal spray solution, 10 μg once daily for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study: NCT05234580
Drug: PA9159 nasal spray solution, 20 μg once daily for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study: NCT05234580
Drug: PA9159 nasal spray solution, 40 μg once daily for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study: NCT05234580
Drug: Placebo nasal spray solution without PA9159, once daily for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study: NCT05727371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection at Day 0
Study: NCT05860868
Drug: 2 cycles induction chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study: NCT05860868
Drug: 3 cycles induction chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study: NCT06343532
Drug: SXC-2023
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg capsules
Study: NCT06343532
Drug: SXC-2023 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg capsules
Study: NCT06082817
Drug: Oral Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg oral testosterone undecanoate daily
Study: NCT06432452
Drug: Endothelin Receptor Antagonist
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules twice daily
Study: NCT04849000
Drug: SHR-1209 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1209 Placebo
Study: NCT06163807
Drug: Antiasthmatic
Normalized name: ANTIASTHMA,ANTILEUKOTRIENES
Approvals — FDA: no, EMA: no, PMDA: no
Description: real-life
Study: NCT05013086
Drug: 1.48 GBq of 177Lu-AB-3PRGD2
Approvals — FDA: no, EMA: no, PMDA: no
Description: accepted intravenous injection of 177Lu-AB-3PRGD2
Study: NCT06496412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take placebo capsules.
Study: NCT00005931
Drug: SU5416
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06685978
Drug: Xiang Ju Ru Pi Ning capsule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
Study: NCT06695741
Drug: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
Study: NCT06403267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 0.9% normal Saline
Study: NCT05810649
Drug: Freshly manufactured 35 kDa hyaluronan fragment
Normalized name: PALMITOYL FRAGMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
Study: NCT06517511
Drug: R-CHOP Protocol
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study: NCT05889741
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5cc of Normal Saline one time into the stellate ganglion.
Study: NCT06496971
Drug: Microbubble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
Study: NCT00002101
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05338450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent to experimental arm
Study: NCT06548620
Drug: RD06-04 cell infusion
Normalized name: SET,INFUSION ANIMAS #240-04
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T Cells
Study: NCT04693715
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60 injection solution
Study: NCT04693715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection solution
Study: NCT04829214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection
Study: NCT05838885
Drug: YPEG-rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
Study: NCT05838885
Drug: YPEG-rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
Study: NCT04991597
Drug: Lidocaine Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
Study: NCT04991597
Drug: Lidocaine Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
Study: NCT04869124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
Study: NCT06158477
Drug: JYP0035 Experimental Drug Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intervention
Study: NCT05587998
Drug: AZD4041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral doses of AZD4041 as stated in arm description.
Study: NCT06527937
Drug: Epinephrine Injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
Study: NCT06121284
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
Study: NCT06342960
Drug: Standard lymphodepletion regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lymphodepletion regimen
Study: NCT05879432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution
Study: NCT04669392
Drug: 70% Ethanol Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time.
Study: NCT06290687
Drug: Adjuvant systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.
Study: NCT06691802
Drug: Shu Fei Tie placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
Study: NCT06141460
Drug: RRG001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via Subretinal injection. Dosage form: injection solution.
Study: NCT06627478
Drug: US-Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 0.5 IU/kg administered over three periods
Study: NCT06627478
Drug: EU-Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 0.5 IU/kg administered over three periods
Study: NCT06192186
Drug: Placebo combined with SOX (S-1/oxaliplatin) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
Study: NCT06694298
Drug: SYS6020
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion
Study: NCT06695962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 per day for 21 days
Study: NCT06689124
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
Study: NCT06690177
Drug: EscharEx (EX-03)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Study: NCT06690177
Drug: Placebo (Gel vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study: NCT06687993
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral intake for 90 days
Study: NCT06694597
Drug: Astragalus Membranaceus Root
Normalized name: ASTRAGALUS MEMBRANACEUS ROOT POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus tablets 15g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Study: NCT06689514
Drug: alpha receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)
Study: NCT06691061
Drug: JAK Inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC patients treated with JAK inhibitors
Study: NCT06689150
Drug: Drospinetta
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the three different types of POPs, the new POPs Drosperinon 4 mg, Desogestrel 75 pg, and Levonorgestrel 30 pg in healthy female subjects as regard to the contraceptive efficacy, bleeding pattern, acceptability and safety
Study: NCT06686355
Drug: Yiqilishui formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
Study: NCT06306157
Drug: Placebo sugar capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
Study: NCT06067893
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives normal saline for 48 hours post-operatively
Study: NCT04985110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
Study: NCT04898309
Drug: GNR-038, 50 МЕ/ kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
Study: NCT04898309
Drug: GNR-038, 100 МЕ/ kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
Study: NCT04898309
Drug: Berinert®, 20 МЕ/ kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
Study: NCT04898309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
Study: NCT04898309
Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
Study: NCT06548672
Drug: BC3195
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
Study: NCT04989166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06057103
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral
Study: NCT05539911
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mic fentanyl added as an adjuvant
Study: NCT06569784
Drug: [14C]HSK31858
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
Study: NCT06164600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
Study: NCT05948943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Stage 2, participants will receive matching placebo for 24 weeks of the study
Study: NCT04994483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given b.i.d. for 52 weeks.
Study: NCT06404086
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Study: NCT06404086
Drug: Melantonin Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Study: NCT05445804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Chain Triglyceride oil
Study: NCT05857878
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05773586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06398418
Drug: R-5780
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic
Study: NCT06643962
Drug: Idarubincin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
Study: NCT05997615
Drug: AMX-500 (SAR446329)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
Study: NCT05658640
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT04943068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Study: NCT06574360
Drug: S1RA plus Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of an S1R agonist plus placebo as a comparator
Study: NCT06674759
Drug: Tongren-Dahuoluo Bolus Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.72g,2 times a day, oral, for 12 weeks.
Study: NCT06546735
Drug: Vesomni®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
Study: NCT06684379
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of saline solution 0.9% for infusion
Study: NCT06684379
Drug: PRS CK STORM
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PRS CK STORM (dose A) for infusion
Study: NCT06684379
Drug: PRS CK STORM
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PRS CK STORM (dose B) for infusion.
Study: NCT06685965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05781750
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo
Study: NCT06501248
Drug: Placebo (calcined magnesia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
Study: NCT05890573
Drug: Bailing capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Bailing capsules,po,tid,12 weeks
Study: NCT06539260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
Study: NCT06284798
Drug: NNC0650-0013 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0650-0013 will be administered subcutaneously or intravenously.
Study: NCT06284798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration.
Study: NCT05702489
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: a drug to treatment influenza in Chinese adults
Study: NCT05698563
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered ultrasound guided to patients with intermetatarsal bursitis
Study: NCT04914273
Drug: Inhalation Spray
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg salbutamol administered per metered dose inhaler
Study: NCT04914273
Drug: Tablet
Normalized name: TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg salbutamol administered per tablet for ingestion
Study: NCT05665751
Drug: TLC-3595 Dose 1
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05665751
Drug: TLC-3595 Dose 2
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05665751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05035927
Drug: TRYP-0082
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.